Table 7.
Univariate analysis of clinicopathological factors for OS and DFS in patients received NAC (n = 78)
| Variables | OS | DFS | ||
|---|---|---|---|---|
| HR(95% CI) | P value | HR(95% CI) | P value | |
| Age | 0.7963(0.3753–1.689) | 0.5528 | 0.6167(0.3178–1.197) | 0.1531 |
| Gender | 0.5719(0.2129–1.536) | 0.2678 | 0.3019(0.1163–0.7836) | 0.0138 |
| Smoking history | 1.648(0.7097–3.827) | 0.2452 | 2.134(0.976–4.663) | 0.0575 |
| Histology | 0.4711(0.2217–1.001) | 0.0503 | 0.351(0.1761–0.6996) | 0.0029 |
| Histologic grading | 1.425(0.6849–2.964) | 0.3435 | 1.714(0.8874–3.312) | 0.1086 |
| Venous invasion | 0.6148(0.2552–1.482) | 0.2784 | 0.7369(0.3251–1.670) | 0.4645 |
| Pathological stage | 0.3958(0.1894–0.8274) | 0.0137 | 0.3351(0.1717–0.6540) | 0.0014 |
| CMTM1_v17 expression | 0.3095(0.1442–0.6643) | 0.0026 | 0.3655(0.1871–0.7142) | 0.0032 |
P value was calculated using a two-sided log-rank test
NAC neoadjuvant chemotherapy, HR hazard ratio (log-rank), CI confidence interval.
Bold values are significant (P < 0.05)